Chlamydia and Mycoplasma in Coronary Artery Disease
Completed
- Conditions
- AtherosclerosisChlamydia InfectionsCoronary Artery DiseaseMycoplasma Infections
- Interventions
- Other: blood sample analysis - mycoplasma and chlamydia antibodies
- Registration Number
- NCT00561028
- Lead Sponsor
- Hospital de Base
- Brief Summary
To test the association between anti-Chlamydia serum titers and anti-Mycoplasma antibodies with Acute Coronary Syndromes.
- Detailed Description
One hundred and twenty-six patients were divided into 4 groups: Acute Coronary Syndrome with ST-elevation, Non-ST-elevation, stable coronary artery disease, and individuals without coronary disease. Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured at baseline and after 6 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 138
Inclusion Criteria
- Age >18 yrs
- Males and females
- Agreed to sign the informed consent
Exclusion Criteria
- Refusal to sign the informed consent
- Follow-up not possible
- For the "acute" groups, time between the pain beginning and randomization >24 hours
- Active infections
- Use of antimicrobial agents within the last 30 days
- End-stage diseases with life expectancy <6 months
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 blood sample analysis - mycoplasma and chlamydia antibodies ST-elevation acute myocardial infarction. 3 blood sample analysis - mycoplasma and chlamydia antibodies known coronary artery disease, either asymptomatic or with stable angina. 4 blood sample analysis - mycoplasma and chlamydia antibodies blood donors without known coronary artery disease. 2 blood sample analysis - mycoplasma and chlamydia antibodies high-risk unstable angina or non-ST-elevation myocardial infarction.
- Primary Outcome Measures
Name Time Method Test the hypothesis that patients with acute coronary syndromes have higher levels of Chlamydia pneumonia and Mycoplasma pneumonia antibodies in comparison with patients with stable coronary artery disease or controls. 6 months
- Secondary Outcome Measures
Name Time Method